Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

SkinBioTherapeutics PLC

SkinBioTherapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.88
  • Today's Change0.125 / 1.16%
  • Shares traded849.95k
  • 1 Year change-48.82%
  • Beta2.5466
Data delayed at least 15 minutes, as of Sep 23 2024 13:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SkinBioTherapeutics plc is a United Kingdom-based life science company focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis.

  • Revenue in GBP (TTM)161.65k
  • Net income in GBP-2.88m
  • Incorporated2015
  • Employees11.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SBTX:LSE since
announced
Transaction
value
Dermatonics LtdDeal completed25 Jan 202425 Jan 2024Deal completed-26.27%3.73m
Data delayed at least 15 minutes, as of Sep 23 2024 13:05 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ImmuPharma PLC-69.96k-2.46m7.37m5.00--2.74-----0.0065-0.0065-0.00020.0065-0.019-----13,992.00-66.99-86.13-111.20-106.39-------8,634.98---7.270.00------23.26------
Synairgen plc0.00-8.41m7.55m36.00--0.5966-----0.0418-0.04180.000.06290.00----0.00-44.55-54.01-51.06-60.02------------0.00------52.35---26.64--
Genflow Biosciences PLC0.00-1.63m7.61m5.00--8.76-----0.0056-0.00560.000.00250.00----0.00-88.30---105.34--------------0.00-------21.97------
Cizzle Biotechnology Holdings PLC0.00-1.72m7.93m67.00--4.83-----0.0048-0.00480.000.00410.00-------76.69-144.15-82.81-167.75-----------0.8050.00-------88.27------
LungLife AI Inc21.77k-3.35m8.25m15.00--0.5121--379.18-0.126-0.1260.00080.23370.0027--2.901,451.33-42.18---47.78--100.00---15,403.45------0.0259--91.67--28.83------
Oxford Biodynamics PLC617.00k-11.11m11.73m45.00--4.69--19.00-0.0643-0.06430.00350.0080.04871.200.37913,711.11-87.64-39.72-114.28-45.5241.49---1,800.32-1,324.620.6156-87.720.7873--231.17-15.53-61.34---1.60--
OptiBiotix Health PLC644.00k-2.04m16.90m5.00--1.77--26.23-0.023-0.0230.00710.09730.06151.771.31128,800.00-19.4616.82-19.9017.5249.6953.03-316.61183.496.62-4.870.00100.1440.924.60-178.82------
Hemogenyx Pharmaceuticals PLC0.00-6.69m19.78m17.00--6.15-----0.0061-0.00610.000.00240.00----0.00-101.47-82.19-112.85-95.97-----------28.030.5144-------68.14--36.68--
Skinbiotherapeutics PLC161.65k-2.88m24.30m11.00--5.60--150.35-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Arecor Therapeutics PLC4.57m-8.55m25.86m50.00--2.20--5.66-0.2793-0.27930.14930.31110.2462--1.3391,460.00-46.06---60.53-------187.05--2.02--0.0343--90.30--7.62------
Sareum Holdings Plc0.00-4.26m27.53m5.00--42.97-----0.0614-0.06140.000.00590.00----0.00-160.20-71.41-195.05-81.48-------19,709.24---6.610.00-------46.96------
Shield Therapeutics PLC20.88m-36.17m28.94m73.00--53.49--1.39-0.0477-0.04770.02740.00070.47234.061.69286,068.50-81.80-56.68-136.41-67.4434.6552.20-173.18-365.890.8968-15.290.9736--137.951.9533.13---2.50--
Incanthera PLC0.00-1.55m31.33m7.00---------0.0189-0.01890.00-0.00610.00----0.00-852.34-115.31---153.87---------------------12.76------
Data as of Sep 23 2024. Currency figures normalised to SkinBioTherapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

17.97%Per cent of shares held by top holders
HolderShares% Held
Yarra Investment Management Ltd.as of 30 Nov 202313.82m6.83%
Odd Asset Management Ltd.as of 05 Jan 202313.17m6.51%
Unicorn Asset Management Ltd.as of 08 Apr 20247.89m3.90%
Evelyn Partners Investment Management LLPas of 31 Dec 20231.46m0.72%
More ▼
Data from 30 Jun 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.